Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. A common feature of these illnesses is the loss of the natural myelin sheath, a cover protecting and nurturing the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or even curing these diseases. Rewind´s team has extensive research and development expertise and a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M-Ventures, PMV, Gemma Frisius Fonds, CD3/ KU Leuven and Sunstone Life Science Ventures.